See more : Mascot Mines Inc. (MSLM) Income Statement Analysis – Financial Results
Complete financial analysis of Anixa Biosciences, Inc. (ANIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anixa Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hopscotch Global PR Group (HOP.PA) Income Statement Analysis – Financial Results
- Kidztech Holdings Limited (6918.HK) Income Statement Analysis – Financial Results
- Value HR Co.,Ltd. (6078.T) Income Statement Analysis – Financial Results
- Bunzl plc (BZLFF) Income Statement Analysis – Financial Results
- Zenlabs Ethica Limited (ZENLABS.BO) Income Statement Analysis – Financial Results
Anixa Biosciences, Inc. (ANIX)
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 210.00K | 2.47B | 512.50K | 0.00 | 250.00K | 1.11M | 362.50K | 300.00K | 9.26M | 3.67M | 388.85K | 940.01K | 1.00M | 730.68K | 1.06M | 2.06M | 486.85K | 508.65K | 439.79K | 494.46K | 244.22K | 5.19M | 1.69M | 1.47M | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 300.00K |
| Cost of Revenue | 161.00K | 42.00K | 385.00K | 90.16K | 166.25K | 768.41K | 104.56K | 217.42K | 3.65M | 1.99M | 316.66K | 3.87K | 34.08K | 82.31K | 65.69K | 95.59K | 160.36K | 156.45K | 719.63K | 176.11K | 175.94K | 1.87M | 697.64K | 463.63K | -300.00K | -300.00K | -300.00K | -100.00K | -100.00K | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 49.00K | 2.47B | 127.50K | -90.16K | 83.75K | 344.09K | 257.94K | 82.58K | 5.61M | 1.68M | 72.19K | 936.14K | 969.11K | 648.37K | 990.11K | 1.97M | 326.49K | 352.21K | -279.84K | 318.35K | 68.28K | 3.32M | 993.13K | 1.01M | 400.00K | 400.00K | 400.00K | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 300.00K |
| Gross Profit Ratio | 23.33% | 100.00% | 24.88% | 0.00% | 33.50% | 30.93% | 71.16% | 27.53% | 60.58% | 45.79% | 18.57% | 99.59% | 96.60% | 88.74% | 93.78% | 95.37% | 67.06% | 69.24% | -63.63% | 64.38% | 27.96% | 63.93% | 58.74% | 68.50% | 400.00% | 400.00% | 400.00% | 200.00% | 200.00% | 200.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 4.77M | 6.70M | 6.19M | 4.38M | 5.47M | 6.81M | 1.60M | 1.56M | 711.39K | 1.19M | 0.00 | 2.21M | 3.12M | 3.01M | 4.12M | 4.13M | 3.40M | 4.61M | 2.27M | 2.16M | 1.81M | 1.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.90M | 2.40M | 2.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.29M | 7.17M | 7.07M | 5.60M | 5.66M | 6.91M | 4.41M | 2.71M | 5.51M | 6.41M | 7.99M | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.29M | 7.17M | 7.07M | 5.60M | 5.66M | 6.91M | 4.41M | 2.71M | 5.51M | 6.41M | 7.99M | 2.86M | 2.87M | 2.89M | 4.19M | 3.83M | 2.41M | 3.37M | 1.92M | 1.52M | 1.38M | 2.18M | 4.60M | 5.83M | 8.30M | 7.20M | 6.40M | 2.20M | 1.00M | 1.00M | 2.90M | 2.00M | 1.50M | 1.40M | 1.20M | 1.30M | 1.30M | 1.90M | 2.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 418.75K | 0.00 | -13.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.06M | 13.88M | 13.26M | 9.98M | 11.56M | 14.05M | 6.33M | 4.59M | 6.55M | 6.72M | 7.99M | 5.07M | 6.00M | 5.90M | 8.31M | 7.96M | 5.53M | 7.98M | 4.19M | 3.68M | 3.19M | 6.62M | 4.60M | 6.09M | 8.60M | 7.50M | 6.70M | 6.20M | 3.50M | 3.80M | 2.90M | 2.00M | 1.50M | 1.50M | 1.30M | 1.40M | 1.40M | 1.90M | 2.00M |
| Cost & Expenses | 11.22M | 13.88M | 13.65M | 9.98M | 11.72M | 14.82M | 6.44M | 4.81M | 10.20M | 8.71M | 8.31M | 5.07M | 6.03M | 5.98M | 8.38M | 8.05M | 5.69M | 8.14M | 4.91M | 3.86M | 3.36M | 8.50M | 5.30M | 6.56M | 8.30M | 7.20M | 6.40M | 6.10M | 3.40M | 3.70M | 2.90M | 2.00M | 1.50M | 1.50M | 1.30M | 1.40M | 1.40M | 1.90M | 2.00M |
| Interest Income | 1.08M | 104.00K | 2.32K | 33.92K | 71.35K | 45.97K | 19.44K | 12.53K | 17.62K | 8.60K | 125.00 | 3.46K | 2.52K | 4.88K | 20.81K | 37.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 104.00K | 322.00 | 0.00 | 0.00 | 0.00 | 500.46K | 519.95K | 451.91K | 1.26M | 1.11M | 7.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 46.00K | 42.00K | 59.86K | 90.16K | 466.31K | 343.73K | 368.51K | 358.63K | 337.81K | 314.45K | 125.00 | 7.23K | 7.98K | 8.36K | 10.61K | 10.67K | 9.89K | 15.07K | 14.71K | 17.00K | 33.08K | 86.47K | 166.50K | 261.80K | 300.00K | 300.00K | 300.00K | 100.00K | 100.00K | 100.00K | -200.00K | -200.00K | -200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 |
| EBITDA | -10.97M | -13.73M | -13.08M | -10.00M | -11.00M | -13.36M | -4.14M | -4.14M | -601.85K | -8.03M | -8.97M | -4.24M | -6.77M | -5.25M | -7.32M | -5.98M | -5.45M | -7.61M | -4.45M | -3.35M | -3.09M | -3.22M | -3.44M | -4.82M | -7.90M | -6.80M | -6.00M | -5.90M | -3.20M | -3.50M | -3.00M | -2.10M | -1.60M | -1.30M | -1.10M | -1.20M | -1.20M | -1.80M | -1.70M |
| EBITDA Ratio | -5,221.43% | -0.56% | -2,552.44% | 0.00% | -4,234.48% | -1,148.71% | -1,569.00% | -1,379.28% | -6.37% | -128.73% | -2,036.14% | -439.47% | -500.18% | -726.46% | 178.05% | -296.14% | -1,065.76% | -1,496.61% | -1,012.10% | -677.10% | -1,263.61% | -7.74% | -203.32% | -327.67% | -7,600.00% | -6,900.00% | -6,600.00% | -6,500.00% | -3,600.00% | -3,700.00% | -3,000.00% | -2,100.00% | -1,600.00% | -1,600.00% | -1,300.00% | -1,300.00% | -1,200.00% | -1,800.00% | -566.67% |
| Operating Income | -11.01M | -13.88M | -13.14M | -9.98M | -11.47M | -14.29M | -6.08M | -4.51M | -944.76K | -5.04M | -7.92M | -4.13M | -5.03M | -5.25M | -7.32M | -5.99M | -5.49M | -7.63M | -4.47M | -3.36M | -3.12M | -3.31M | -3.60M | -5.09M | -8.20M | -7.10M | -6.30M | -6.00M | -3.30M | -3.60M | -2.80M | -1.90M | -1.40M | -1.40M | -1.20M | -1.30M | -1.30M | -1.80M | -1.70M |
| Operating Income Ratio | -5,243.33% | -0.56% | -2,563.06% | 0.00% | -4,588.50% | -1,284.41% | -1,676.02% | -1,503.00% | -10.21% | -137.54% | -2,036.17% | -439.84% | -501.23% | -718.27% | -693.35% | -290.31% | -1,128.14% | -1,499.58% | -1,015.44% | -680.54% | -1,277.15% | -63.79% | -213.17% | -345.46% | -8,200.00% | -7,100.00% | -6,300.00% | -6,000.00% | -3,300.00% | -3,600.00% | -2,800.00% | -1,900.00% | -1,400.00% | -1,400.00% | -1,200.00% | -1,300.00% | -1,300.00% | -1,800.00% | -566.67% |
| Total Other Income/Expenses | 1.08M | 104.00K | 7.69K | -114.16K | 71.35K | 45.97K | 1.07M | -507.42K | -434.28K | -4.56M | -2.16M | -118.24K | -1.75M | 73.09K | -9.17M | 167.91K | 34.15K | 26.72K | 14.51K | 4.33K | 0.00 | -2.82M | 0.00 | 0.00 | -300.00K | 100.00K | 600.00K | 600.00K | 400.00K | 200.00K | 200.00K | 200.00K | 200.00K | 300.00K | 200.00K | 100.00K | 0.00 | 1.80M | 1.70M |
| Income Before Tax | -9.93M | -13.77M | -13.13M | -10.09M | -11.82M | -14.24M | -5.01M | -5.02M | -1.38M | -9.61M | -10.08M | -4.25M | -6.78M | -5.18M | -16.49M | -5.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.13M | 0.00 | 0.00 | -8.50M | -7.00M | -5.70M | -5.40M | -2.90M | -3.40M | -2.60M | -1.70M | -1.20M | -1.10M | -1.00M | -1.20M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -4,728.57% | -0.56% | -2,561.55% | 0.00% | -4,727.46% | -1,280.28% | -1,381.79% | -1,672.14% | -14.90% | -261.94% | -2,592.28% | -452.42% | -675.65% | -708.27% | -1,561.76% | -282.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -118.18% | 0.00% | 0.00% | -8,500.00% | -7,000.00% | -5,700.00% | -5,400.00% | -2,900.00% | -3,400.00% | -2,600.00% | -1,700.00% | -1,200.00% | -1,100.00% | -1,000.00% | -1,200.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -280.00K | -181.29K | 40.15K | 175.80K | 289.95K | 500.46K | 12.53K | 17.62K | 1.26M | 1.11M | 430.00 | 600.00K | -73.09K | 9.17M | -167.91K | 259.65K | -26.72K | -14.51K | -4.33K | -4.67K | -23.51K | -32.28K | -120.98K | 300.00K | 0.00 | -500.00K | -600.00K | -300.00K | -200.00K | 200.00K | 100.00K | 100.00K | -300.00K | -100.00K | 0.00 | 100.00K | 1.80M | 1.70M |
| Net Income | -9.81M | -13.49M | -12.95M | -10.13M | -11.99M | -14.00M | -5.01M | -5.02M | -1.38M | -9.61M | -10.08M | -4.25M | -7.38M | -5.18M | -16.49M | -5.82M | -5.46M | -7.60M | -4.45M | -3.36M | -3.11M | -3.29M | -3.57M | -4.96M | -8.50M | -7.10M | -5.80M | -5.40M | -3.00M | -3.40M | -2.80M | -1.80M | -1.30M | -1.10M | -1.10M | -1.30M | -1.40M | -1.80M | -1.70M |
| Net Income Ratio | -4,671.90% | -0.55% | -2,526.17% | 0.00% | -4,797.78% | -1,258.07% | -1,381.79% | -1,672.14% | -14.90% | -261.94% | -2,592.28% | -452.42% | -735.46% | -708.27% | -1,561.76% | -282.17% | -1,121.12% | -1,494.33% | -1,012.14% | -679.66% | -1,275.24% | -63.34% | -211.26% | -337.24% | -8,500.00% | -7,100.00% | -5,800.00% | -5,400.00% | -3,000.00% | -3,400.00% | -2,800.00% | -1,800.00% | -1,300.00% | -1,100.00% | -1,100.00% | -1,300.00% | -1,400.00% | -1,800.00% | -566.67% |
| EPS | -0.32 | -0.44 | -0.45 | -0.46 | -0.61 | -0.79 | -0.41 | -0.57 | -0.14 | -1.00 | -1.17 | -0.53 | -1.01 | -0.79 | -2.70 | -1.02 | -1.20 | -1.81 | -1.14 | -0.92 | -0.94 | -1.10 | -1.26 | -1.81 | -3.29 | -2.79 | -2.29 | -2.24 | -1.35 | -1.59 | -1.37 | -0.91 | -0.68 | -0.68 | -0.68 | -0.68 | -0.91 | -1.14 | -1.14 |
| EPS Diluted | -0.32 | -0.44 | -0.45 | -0.46 | -0.61 | -0.79 | -0.41 | -0.57 | -0.14 | -1.00 | -1.17 | -0.53 | -1.01 | -0.79 | -2.70 | -1.02 | -1.20 | -1.81 | -1.14 | -0.92 | -0.94 | -1.10 | -1.26 | -1.81 | -3.16 | -2.69 | -2.29 | -2.17 | -1.30 | -1.59 | -1.37 | -0.91 | -0.68 | -0.68 | -0.68 | -0.68 | -0.91 | -1.14 | -1.14 |
| Weighted Avg Shares Out | 30.98M | 30.37M | 28.58M | 22.23M | 19.79M | 17.62M | 12.20M | 8.74M | 9.63M | 9.57M | 8.64M | 7.98M | 7.33M | 6.53M | 6.10M | 5.69M | 4.55M | 4.19M | 3.89M | 3.65M | 3.30M | 2.99M | 2.84M | 2.74M | 2.58M | 2.54M | 2.53M | 2.41M | 2.22M | 2.13M | 2.05M | 1.98M | 1.90M | 1.61M | 1.61M | 1.90M | 1.54M | 1.58M | 1.49M |
| Weighted Avg Shares Out (Dil) | 30.98M | 30.37M | 28.58M | 22.23M | 19.79M | 17.62M | 12.20M | 8.74M | 9.63M | 9.57M | 8.64M | 7.98M | 7.33M | 6.53M | 6.10M | 5.69M | 4.55M | 4.19M | 3.89M | 3.65M | 3.30M | 2.99M | 2.84M | 2.74M | 2.69M | 2.64M | 2.53M | 2.49M | 2.31M | 2.13M | 2.05M | 1.98M | 1.90M | 1.61M | 1.61M | 1.90M | 1.54M | 1.58M | 1.49M |
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors SAN JOSE, Calif. , May 21, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention...
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
– Company currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines – SAN JOSE, Calif., May 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer,...
Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja
Dr. Amit Kumar interviewed in latest episode, 'The Vaccine That Could End Breast Cancer' SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced...
Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024
SAN JOSE, Calif., April 30, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the Sidoti Micro-Cap Virtual Conference, taking place May 8-9, 2024.
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
SAN JOSE, Calif., April 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Sanjay Juneja, MD to its Cancer Business Advisory Board.
Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
SAN JOSE, Calif., March 14, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2024 Annual Meeting of Stockholders (the "Meeting") on Thursday,...
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
SAN JOSE, Calif., March 11, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO of Anixa, will participate in the...
Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
Dose escalation for fourth patient follows successful completion of first cohort SAN JOSE, Calif. , Feb. 12, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that...
Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
Conference Investment Track spotlights promising and emerging biotech and healthcare companies advancing the field of oncology SAN JOSE, Calif. , Jan. 29, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of...
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
Broad coverage extended to Japan and related regions SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has...
Source: https://incomestatements.info
Category: Stock Reports